| Stage | XRAY | % of rev | CNMD | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $898M | 100.00% | $336M | 100.00% | XRAY ×2.68 |
| Gross profit | $493M | 54.90% | $189M | 56.37% | CNMD +1.5pp |
| Operating income | $82M | 9.13% | $37M | 11.07% | CNMD +1.9pp |
| Pre-tax income | $72M | 8.02% | $26M | 7.75% | XRAY +0.3pp |
| Net income | $36M | 4.01% | $20M | 5.90% | CNMD +1.9pp |
| Stage | XRAY | CNMD | Gap · A − B |
|---|---|---|---|
| Revenue | $898M100.00% | $336M100.00% | XRAY ×2.68 |
| Gross profit | 54.90%$493M | 56.37%$189M | CNMD +1.5pp |
| Operating income | 9.13%$82M | 11.07%$37M | CNMD +1.9pp |
| Pre-tax income | 8.02%$72M | 7.75%$26M | XRAY +0.3pp |
| Net income |
| 4.01%$36M |
| 5.90%$20M |
| CNMD +1.9pp |
No shared counterparties.